je.st
news
Results of Phase 2 Study of Mercks Investigational Beta-Lactamase Inhibitor Relebactam Presented at ICAAC/ICC 2015
2015-09-18 21:00:00| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. Company Initiates Pivotal Phase 3 Studies Evaluating Relebactam in Combination with Imipenem/Cilastatin for Treatment of Serious Bacterial Infections KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that a Phase 2 study of relebactam, the companys investigational beta-lactamase inhibitor for the treatment, in combination with imipenem/cilastatin (an approved carbapenem antibiotic), of complicated intra-abdominal infections, met its primary endpoint, and that Merck is now initiating pivotal Phase 3 studies. Language: English Contact: MerckMedia:Doris Li, (908) 246-5701Ian McConnell, (973) 901-5722orInvestor:Teri Loxam, (908) 740-1986Justin Holko, (908) 740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: results
study
presented
phase
Category:Biotechnology and Pharmaceuticals